A novel CRISPR-based technology can spread within bacterial populations to eliminate antibiotic resistance. In a potential breakthrough for tackling antibiotic resistance, researchers from the ...

Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

A Dartmouth study finds that molecular hitchhikers living within bacteria can make their hosts extra resistant to medical treatment by corralling them into tightly packed groups. The findings ...

Vaxcyte (PCVX) is a clinical-stage vaccine innovation company focused on developing next-generation vaccines to protect people from serious bacterial infectious diseases. While Vaxcyte is still a ...

Evolution is perhaps the most extraordinary story ever told—a tale spanning billions of years that connects every living thing on Earth through an intricate ...

Learn how BeSEC enables precise analysis of antibody aggregation and molecular weight through dual-angle light scattering.

Precision-fermented fats are the new invention that promises to be better for the heart. Here is exactly what it is, how it ...

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

Meningococcal disease is a rare but very serious illness caused by bacteria that can lead to infections of the brain and spinal cord (meningitis) or severe blood infections. It can affect anyone, but ...

XDR typhoid spreads across regions, weakening key antibiotics and raising urgent calls for vaccination, new drugs and stronger global surveillance.

The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies ...